Weight CDX 1401 is a celldex compund not Astex. This may eventually beneifit Celldex not Astex . Celldex is a very interesting stock by the way I have owned it for some time. The use of Decitabine in this combo wont benefit Astex because it will be generic by the time this gets approved.
Another great patent just issued to Astex.
United States Patent 8,445,502
Bearss , et al. May 21, 2013
Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same
The present invention relates to pharmaceutical formulations comprising the protein kinase inhibitor, MP470, and methods of using same in treating conditions involving undesirable cell proliferation, such as cancer.
Inventors: Bearss; David J. (Cedar Hills, UT), Joshi-Hangal; Rajashree (Pleasanton, CA), Liu; Xiao-Hui (Sandy, UT), Phiasivongsa; Pasit (Brentwood, CA), Redkar; Sanjeev G. (Hayward, CA), Vankayalapati; Hariprasad (Draper, UT)
Applicant: Name City State Country Type
Bearss; David J. Joshi-Hangal; Rajashree Liu; Xiao-Hui Phiasivongsa; Pasit Redkar; Sanjeev G. Vankayalapati; Hariprasad Cedar Hills Pleasanton Sandy Brentwood Hayward Draper UT CA UT CA CA UT US US US US US US
Assignee: Astex Pharmaceuticals, Inc. (Dublin, CA)
Appl. No.: 12/906,640
Filed: October 18, 2010
Current U.S. Class: 514/267
Current International Class: A01N 43/54 (20060101); A61K 31/505 (20060101)
Field of Search: 514/267
References Cited [Referenced By]
Foreign Patent Documents
WO 2005/037825 Apr., 2005 WO
Primary Examiner: Leeser; Erich A
Attorney, Agent or Firm: Seed IP Law Group PLLC
Parent Case Text
What is claimed is:
1. A method of treating small cell lung cancer in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of an oral pharmaceutical formulation comprising a pharmaceutically acceptable excipient and a hydrochloride sale of MP470, wherein MP470 has the following structure: ##STR00007## , wherein the pharmaceutical formulation is delivered in combination with at least on
This phase I trial studies the side effects and immune response to DEC-205/NY-ESO-1 fusion protein CDX-1401 and decitabine in patients with myelodysplastic syndrome or acute myeloid leukemia. DEC-205-NY-ESO-1 fusion protein, called CDX-1401, is a full length NY-ESO-1 protein sequence fused to a monocolonal antibody against DEC-205, a surface marker present on many immune stimulatory cells. This drug is given with another substance called PolyICLC, which acts to provoke any immune stimulatory cells which encounter the NY-ESO-1-DEC-205 fusion protein to produce an immune response signal against NY-ESO-1. Immune cells which have thus been primed to react against NY-ESO-1 may then attack myelodysplastic or leukemic cells which express NY-ESO-1 after exposure to the drug decitabine. The chemotherapy drug decitabine is thought to act in several different ways, first, it may directly kill cancer cells, secondly, the drug can cause cancer cells to re-express genes that are turned off by the cancer, including the gene for NY-ESO-1. Giving DEC-205/NY-ESO-1 fusion protein (CDX-1401) and polyICLC together with decitabine may allow the immune system to more effectively recognize cancer cells and kill them.
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
This study is not yet open for participant recruitment.
Verified May 2013 by Roswell Park Cancer Institute
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Roswell Park Cancer InstituteClinicalTrials.gov Identifier:
First received: April 12, 2013
Last updated: May 7, 2013
Last verified: May 2013
History of Changes